Aglaia Oncology Funds is a private equity and venture capital firm focused on early‑stage life sciences, technology and healthcare companies with a emphasis on oncology. It backs tools, technologies and approaches in cancer drug development and usually invests in European companies. Based in Bilthoven, Netherlands, the firm takes an active role in the strategic and operational development of its portfolio. It typically commits up to EUR 8 million per company to support growth and drug development efforts, and was established in the early 2000s.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.